Sanofi SA
SNW
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
74,846
Stocks News & Analysis
stocks
7 undervalued US stocks that crushed earnings
Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks
Undervalued ASX share hitting on all cylinders
Strong performance across all segments in latest earnings release.
stocks
Investor Playbook: Can your portfolio handle what’s next?
Testing portfolio resilience in an uncertain market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.40 | 39.10 | -0.42% |
| CAC 40 | 8,372.15 | 3.24 | 0.04% |
| DAX 40 | 26,654.74 | 95.21 | -0.36% |
| Dow JONES (US) | 52,011.74 | 335.81 | -0.64% |
| FTSE 100 | 10,916.82 | 14.26 | 0.13% |
| HKSE | 23,753.84 | 116.24 | 0.49% |
| NASDAQ | 24,635.02 | 501.26 | -1.99% |
| Nikkei 225 | 59,662.02 | 1,480.33 | -2.42% |
| NZX 50 Index | 14,303.77 | 130.09 | 0.92% |
| S&P 500 | 7,463.48 | 98.19 | -1.30% |
| S&P/ASX 200 | 9,044.70 | 37.50 | -0.41% |
| SSE Composite Index | 3,602.57 | 31.78 | -0.87% |